(Q44498037)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920395%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

The population attributable fraction as a measure of the impact of warfarin pharmacogenetic testing (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920395%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920395%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Chen Suo

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920395%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Kee Seng Chia

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920395%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Yik Ying Teo

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920395%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

1 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920395%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920395%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920395%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920395%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

1247-1256

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920395%20AND%20SRC:MED&resulttype=core&format=json

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

12 February 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

Genetic determinants of warfarin dosing in the Han-Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

Genetic and clinical predictors of warfarin dose requirements in African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

Estimation of the warfarin dose with clinical and pharmacogenetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

Evaluation of pharmacogenetic algorithm for warfarin dose requirements in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

Singapore Genome Variation Project: a haplotype map of three Southeast Asian populations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

Factors determining the maintenance dose of warfarin in Chinese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

Use and misuse of population attributable fractions.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

Validation of warfarin pharmacogenetic algorithms in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

Pharmacogenetics of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

Proportion of disease caused or prevented by a given exposure, trait or intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

Biostatistics and epidemiology: measuring the risk attributable to an environmental or genetic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.104

21 January 2018

Identifiers

DOI

10.2217/PGS.12.104

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22920395%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference